• BMS-777607: c-Met Inhibitor Evidence and Use

  2026-09-27

  BMS-777607 is an ATP-competitive c-Met inhibitor that also targets Axl, Ron, and Tyro3. Product information reports potent MET-family inhibition and preclinical effects in a murine metastasis model, while a 2026 platelet-differentiation study mentions BMS-777607 only as prior background—not as a compound tested in its optimized protocol.

• FKBP9 Drives Glioblastoma Growth and ER-Stress Resistance

  2026-09-26

  Xu et al. identify FKBP9 as a glioblastoma-associated factor linked to malignant cell behavior, tumor growth, and resistance to endoplasmic reticulum stress inducers. Their findings connect FKBP9 with ASK1–p38 signaling and the IRE1α–XBP1 unfolded protein response, offering a mechanistic framework for studying stress adaptation in glioblastoma.

• Epidermal Growth Factor in 3D Glioma Assays

  2026-09-25

  Pair recombinant human EGF with a streamlined glioblastoma spheroid workflow to test how a defined growth-factor input changes sphere formation—without mistaking growth for stemness. Practical guidance covers dose selection, handling, controls, and interpretation using APExBIO’s characterized research-grade protein.

• PYR-41 and the E1–IRF7 Antiviral Research Frontier

  2026-09-25

  IBDV research links viral VP3 to proteasome-dependent IRF7 loss. This article examines how PYR-41 can help test the role of E1 in that process—and why the distinction between pathway evidence and E1-specific proof matters.

• VX-745 and the Next Questions in p38α MAPK Biology

  2026-09-24

  A mechanistic and translational guide to using VX-745 as a selective p38α MAPK inhibitor—connecting kinase occupancy, activation-loop dephosphorylation, inflammatory readouts, and practical study design without overstating what current evidence establishes.

• EdU Flow Cytometry Assay Kits (Cy5): Practical Guide

  2026-09-24

  EdU Flow Cytometry Assay Kits (Cy5) measure DNA synthesis during the S phase by detecting EdU incorporated into newly synthesized DNA, providing a flow-cytometry readout without harsh DNA denaturation. Use the assay for a defined EdU-pulse endpoint and validated multiplex panels; it does not, by itself, measure long-term population growth or distinguish every source of DNA synthesis.

• CERES–XIAN Axis in Plant dsRNA Immunity

  2026-09-23

  A 2026 study identifies AtCERES and mitochondrial protein AtXIAN as positive regulators of double-stranded RNA-triggered plant immunity, connecting mitochondrial reactive oxygen species to defense signaling. The findings define a pathway distinct from the established RBOHD-dependent ROS route while leaving the initial dsRNA-recognition mechanism unresolved.

• MMP-2-Responsive Liposome Immunotherapy

  2026-09-23

  The reference study develops a cascade-targeted liposome that sequentially delivers the PD-1 pathway peptide AUNP-12 and the IDO inhibitor NLG919 to remodel an immunosuppressive breast-cancer microenvironment. Its main contribution is the integration of PD-L1-associated localization, MMP-2-triggered peptide release, and secondary tumor-cell targeting into one delivery system, offering a mechanistically coherent alternative to nonspecific combination immunotherapy.

• HyperScript™ Reverse Transcriptase for RNA-Seq Validation

  2026-09-22

  HyperScript™ Reverse Transcriptase supports RNA to cDNA conversion when transcript structure, limited template abundance, and downstream qPCR create competing demands. This article translates a recent laying-hen transcriptomics study into practical reverse-transcription and assay-design decisions.

• Moesin as a Biomarker of Endothelial Injury in Sepsis

  2026-09-22

  Chen and colleagues investigated moesin as a circulating indicator and mechanistic contributor to endothelial injury during sepsis. Their patient, mouse, and endothelial-cell experiments linked higher moesin to disease severity, pulmonary vascular leakage, and Rock1/MLC and NF-κB activation, while MSN silencing reduced inflammatory signaling and monolayer hyperpermeability.

• Imatinib (STI571): Practical Research Workflows

  2026-09-21

  Imatinib (STI571) enables controlled interrogation of Abl, PDGF receptor, and c-Kit signaling across kinase, proliferation, and leukemia models. This guide connects routine pathway inhibition with a CML neutrophil extracellular trap workflow inspired by recent TKI research, while emphasizing controls, dosing logic, and troubleshooting.

• 2-Thio-dCTP for Precision DNA Assays

  2026-09-21

  2-Thio-dCTP enables controlled testing of DNA polymerase selectivity, site-specific DNA modification, and DNA–protein recognition. This workflow-focused guide also explains how to relate modified-DNA assays to the SCP4–H3T3 chromosome-stability findings without treating the nucleotide analog as a direct phosphatase probe.

• Tunicamycin Workflows for ER Stress Research

  2026-09-20

  Turn Tunicamycin into a controlled N-glycosylation inhibitor workflow for mapping ER stress, immune dysfunction, and macrophage inflammation. This guide connects biochemical pathway disruption with practical RAW264.7 and splenic CD4+ T-cell assay designs, rescue experiments, and troubleshooting decisions.

• Danazol as a Precision Perturbation Tool

  2026-09-19

  Danazol and Danocrine are examined here through a model-design lens, connecting receptor pharmacology with HPG-axis assays. The article explains how a 2025 rat study supports more rigorous interpretation of steroidogenic and puberty-related endpoints.

• Ciprofloxacin–Tetracycline Antagonism at Single-Cell Scale

  2026-09-18

  This study shows that ciprofloxacin–tetracycline antagonism is driven not simply by slower population growth, but by increased survival of individual bacterial cells under combination treatment. Microfluidic single-cell measurements further link the interaction to initial growth rate, nutrient availability, and distinct SOS-response states among ciprofloxacin-exposed cells.

3661 records 1/245 page Next 12345 下5页 Last page